133 related articles for article (PubMed ID: 35891263)
1. Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis.
Cheng H; Peng Z; Si S; Alifu X; Zhou H; Chi P; Zhuang Y; Mo M; Yu Y
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891263
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis.
Cheng H; Peng Z; Si S; Alifu X; Zhou H; Chi P; Zhuang Y; Mo M; Yu Y
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632554
[TBL] [Abstract][Full Text] [Related]
3. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.
Du Y; Chen L; Shi Y
Hum Vaccin Immunother; 2022 Nov; 18(5):2062983. PubMed ID: 35499517
[TBL] [Abstract][Full Text] [Related]
4. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis.
Zhang X; Xia J; Jin L; Wu Y; Zheng X; Cao X; Meng X; Li J; Zhu F
Hum Vaccin Immunother; 2023 Aug; 19(2):2221146. PubMed ID: 37344370
[TBL] [Abstract][Full Text] [Related]
6. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
[TBL] [Abstract][Full Text] [Related]
8. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
[TBL] [Abstract][Full Text] [Related]
9. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.
Zhang L; Chen H; Yang S; Zhao Y; Shen X; He X; Ye H; Wang D; Lou J; Wang Y; Wu S
Front Immunol; 2022; 13():990071. PubMed ID: 36203574
[TBL] [Abstract][Full Text] [Related]
10. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
11. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
Peng P; Feng C; Hu J; He C; Deng H; Fan Q; Xiang J; Tang G; Jiang ML; Hu F; Li F; Wang K; Tang N; Tang XP; Huang A
iScience; 2022 Nov; 25(11):105465. PubMed ID: 36338432
[TBL] [Abstract][Full Text] [Related]
12. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
[TBL] [Abstract][Full Text] [Related]
13. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
[TBL] [Abstract][Full Text] [Related]
15. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
Khong KW; Liu D; Leung KY; Lu L; Lam HY; Chen L; Chan PC; Lam HM; Xie X; Zhang R; Fan Y; To KK; Chen H; Yuen KY; Chan KH; Hung IF
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214619
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages.
Jahrsdörfer B; Proffen M; Scholz J; Hägele J; Ludwig C; Vieweg C; Grempels A; Fabricius D; Lotfi R; Körper S; Adler G; Schrezenmeier H
Front Immunol; 2022; 13():920210. PubMed ID: 35795665
[TBL] [Abstract][Full Text] [Related]
17. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains.
Zhang Z; He Q; Zhao W; Li Y; Yang J; Hu Z; Chen X; Peng H; Fu YX; Chen L; Lu L
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887928
[TBL] [Abstract][Full Text] [Related]
18. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
19. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
20. Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study.
Li J; Xie H; Chen W; Chen M; Bai S; Zhao W; Zhou T; Gao P; Zhang L; Wang Q; Pang X; Huang C; Wu J
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
